Search clinical trials for: EP0062

Total 48 results

Ellipses Pharma

Recruiting

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

Metastatic Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States, Spain, United Kingdom
Ellipses Pharma

Recruiting

Study to Evaluate the Safety and Tolerability of EP0042

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia, Netherlands, United Kingdom
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
Taizhou HoudeAoke Biomedical Co., Ltd.

Not yet recruiting

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

China
Ellipses Pharma

Recruiting

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Advanced Solid Tumor

United States, Spain, United Kingdom
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Guangdong Fapon Biopharma Inc.

Recruiting

A Study to Investigate FP002 in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Eisai Inc.

Completed

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Metabolism and Excretion

United States
Eisai Inc.

Completed

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Insomnia

United States
Eisai Inc.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Elderly | Chronic Insomnia | Adults

United States
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine
Escient Pharmaceuticals, Inc

Recruiting

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

Chronic Inducible Urticaria

Spain, United States, Germany, Canada, Netherlands
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Escient Pharmaceuticals, Inc

Recruiting

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Chronic Spontaneous Urticaria

Spain, United States, Germany, Canada, Poland, Netherlands
Escient Pharmaceuticals, Inc

Active, not recruiting

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Atopic Dermatitis

United States, Canada
Eisai Inc.

Completed

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

CNS

United States
Taizhou HoudeAoke Biomedical Co., Ltd.

Unknown

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Melanoma

China
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Breast Cancer | Chemotherapy-induced Neutropenia

Spain, United States, Argentina, Chile, India, Malaysia, Puerto Rico, Russian Federation
Dr. Joseph Griffin

Completed

Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)

Cerumen Impaction of Both Ears

United States
Xiangya Hospital of Central South University

Not yet recruiting

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

Parkinson's Disease

China
Afexa Life Sciences Inc

Completed

A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

Canada
Sandoz

Completed

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (PIONEER)

Breast Cancer | Chemotherapy Associated Neutropenia

Czech Republic, Hungary, Latvia, Russian Federation, Slovakia, Ukraine
CV Technologies
Capital Health, Canada

Completed

Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

Upper Respiratory Infection

Canada
CV Technologies

Completed

Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults

Healthy

United States
National Cancer Institute (NCI)

Recruiting

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial Cancer

United States
Shanghai 6th People's Hospital

Not yet recruiting

Sinomenine Versus Glucocorticoid for Knee OA

Knee Osteoarthritis
CV Technologies
University of Alberta; Capital Health, Canada

Completed

Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.

Upper Respiratory Infection

Canada
Sandoz
Sandoz GmbH

Terminated

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Severe Chronic Neutropenia

Germany, Sweden
Ellipses Pharma

Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Gastric Cancer | Small-cell Lung Cancer

China, Korea, Republic of, Taiwan
Ellipses Pharma

Completed

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Ovarian Cancer

United States, United Kingdom, Hungary
Taizhou HoudeAoke Biomedical Co., Ltd.

Unknown

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Small-cell Lung Cancer

China
Taizhou HoudeAoke Biomedical Co., Ltd.

Unknown

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Digestive System Neoplasms

China
Eisai Co., Ltd.

Completed

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

Sleep Initiation and Maintenance Disorders

Japan
Eisai Inc.

Completed

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Insomnia

United States
Eisai Co., Ltd.

Completed

A Study of Lemborexant in Chinese Participants With Insomnia Disorder

Sleep Initiation and Maintenance Disorders

Taiwan, China
Eisai Co., Ltd.

Recruiting

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Eisai Co., Ltd.

Completed

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

Healthy Volunteer

China
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sleep Apnea, Obstructive | Respiration Disorders | Pulmonary Disease, Chronic Obstructive

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Parkinson's Disease

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant-Alcohol Interaction in Healthy Subjects

Healthy Subjects

Canada
Eisai Inc.

Completed

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (SUNRISE 1)

Insomnia

United States, Spain, United Kingdom, Italy, Germany, France, Canada
Eisai Inc.

Completed

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Insomnia Disorder

United States
Eisai Inc.
Purdue Pharma LP

Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Insomnia Disorders

Canada
Eisai Inc.
Purdue Pharma LP

Completed

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

Healthy Subjects

United States

3

Subscribe